Core Points - Hemogenyx Pharmaceuticals plc has issued a total of 123,377 new Ordinary Shares for various reasons, including the exercise of warrants and the vesting of Restricted Stock Units [2][4] - The company raised £190,000 through the exercise of warrants for 105,556 new Ordinary Shares at an exercise price of £1.80 [3] - A total of 6,000 new Ordinary Shares were issued following the vesting of Restricted Stock Units [4] - Additionally, 11,821 new Ordinary Shares were issued under a Deed of Variation at a price of £8.84 per share [5] - The total number of issued shares will reach 6,041,255 upon admission of the new shares, which will be used for shareholder calculations regarding interest notifications [7] - The new shares will be admitted to the FCA official list and trading on the LSE main market, expected around 8:00 a.m. on December 23, 2025 [6] Company Overview - Hemogenyx Pharmaceuticals is a clinical stage biopharmaceutical group focused on developing new medicines and treatments for blood and autoimmune diseases [11] - The company is developing several distinct and complementary product candidates, along with platform technologies for novel product development [11]

Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 12, 2024 THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorporation or Organization) England and Wales 2834 Not Applicable (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) Caspia ...